For instance, at Sanford Health, Collett et al. (2023) retrospectively analyzed data from patients with preemptive pharmacogenomic profiles, including CYP2D6. The authors identified 114 poor CYP2D6 PMs prescribed metoprolol, matched with 114 NMs, and reported a significant difference between the two groups in the incidence of bradycardia. The gene discussed is CYP2D6; the disease is Bradycardia.